Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor

Japanese Journal of Urology

Volumn 104, Issue 1, 2013, Pages 1-5

  Fujita, Naoyuki ^a   Okegawa, Takatsugu ^a   Tambo, Mitsuhiro ^a   Shishido, Toshihide ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Prognostic factor; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

EID: 84873047843     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol.104.1     Document Type: Article

References (13)

1. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF and Senger DR: Increased expression of vasucular permeability factor (vasucular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol, 143, 1255-1262, 1993. (Pubitemid 24057094)
2. Jacobsen J, Rasmuson T, Grankvist K and Ljungberg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol, 163, 343-347, 2000.
3. Ferrara N, Houck KA, Jakeman LB, Winer J and Leung DW: The vascular endothelial growth factor family of polypeptides. J. Cell Biochem, 47, 211-218, 1991.
4. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271 -275, 1999.
5. Sato K, Tsuchiya N, Sasaki R, Shimada N, Satoh S, Ogawa O and Kato T: Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma Jpn J Cancer Res, 90, 874-879, 1999. (Pubitemid 29431367)
6. Baccala AA, Zhong H, Clift SM, Nelson WG, Marshall FF, Passe TJ, Gambill NB and Simons JW: Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer. Urology, 51, 327-332, 1998. (Pubitemid 28093192)
7. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S and Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin Oncol, 22, 454-463, 2004.
8. Bukowski RM, Negrier S and Elson P: Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res, 10, 6310-6314, 2004.
9. Tanimoto S, Fukumori T, EI-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M and Kanayama H: Prognostic significance of serum hepatocyte growth factor in clear cell renal carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest, 55, 106-111, 2008.
10. Onishi T, Oishi Y, Goto H, Yanada S and Abe K: Gender as a prognostic factor in patients with renal cell carcinoma BJU Int, 90, 32-36, 2002.
11. Dosquet C, Coudert MC, Lepage E, Cabane J and Richard F: Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res, 3, 2451-2458, 1997. (Pubitemid 28133167)
12. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C and Blay JY: Groupe Francais d'Immunotherapie: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol, 22, 2371-2378, 2004. (Pubitemid 41115394)
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C and Bukowski RM: Sorafenib for treatment of renal cell Carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 27, 3312-3318, 2009.